October 2020
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Archive for the ‘Cancer Medicine’ Category

The number of cells in a tissue is determined by the balance between cell division and cell death.

Uncontrollable cell division leads to the formation of abnormal growths called tumors. Tumors can be benign or malignant.

Benign Tumors

Benign tumors are slow-growing and constrained by surrounding connective tissue so they do NOT spread to other organs.

They can still be harmful or even kill by pressing on nearby nerves, blood vessels, or brain tissue. Examples of benign tumors include pituitary tumors which may press on optic nerves and cause loss of vision.

There are well over 200 different types and varieties of cancers that are known today, and some may not have been found yet as well.

Cancer in general is an abnormal class of disease in which cellular growth gets out of control.

This happens because cells multiply and divide too quickly causing the formation of tumors, which are masses or lumps that interfere with many different body organs and change the number of hormones released as well.

The classification of cancer depends on what cell has been affected at the start of the abnormal growth.

Cancer is a disease that affects the cells of the body.

Cells are extremely small units that build together and form all living things, which include human beings. In any given person’s body, you will find billions of cells.

Cancer occurs when unusual and abnormal cells grow and spread very quickly.

Normal cells in the body divide, grow to a certain size, and then stop. Over time, cells will even die.

Cancer cells do not follow this normal pattern of division and growth, however.

It is important to understand the difference between a benign tumor, and a malignant tumor, and what it means to a cancer sufferer – as both have a significant bearing on the prognosis (life expectancy) of a cancer patient.

Although both do have certain similarities, they have one major significant difference (the difference between life and death at a late-stage development).

Benign tumors – are not usually life-threatening, and are more of a nuisance than anything else (benign tumors are unlikely to cause the fatality of a patient as they cannot metastasize (spread) to other parts of the body.

An estimated 10 million Americans alive today have faced a cancer diagnosis at some time in their life.

Due to advances in medicine, cancer care and treatment have dramatically improved survival rates and overall quality of life.

The improvement is mainly because patients are taking an active role in their cancer treatment.

When you are faced with cancer, remember that no question is inappropriate.

5 questions cancer patients should ask their oncologist:

1. Will cancer and its treatment affect other parts of my body?

Special Procedures

Click on Any Topic

Bone Marrow Transplants

Organ Transplants

Stem Cells

——————————————–

Euthanasia

Physician Assisted Suicide

Medical Topics
  • Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC
    (MedPage Today) -- Long-term data from an early first-line trial of pembrolizumab (Keytruda) plus chemotherapy showed that more than half of patients with advanced non-squamous non-small cell lung cancer (NSCLC) remained alive at 3 years. In cohort...
  • Suze Orman's Schwannoma
    (MedPage Today) -- Financial advisor, author and former CNBC host Suze Orman has always stressed that it is a mistake for people to ignore their money problems. Now she wants you to know that "the most vital and stupid mistake I could ever make...
  • 'License' to Smoke After Negative Lung Screening?
    (MedPage Today) -- Some individuals appear to interpret a negative low-dose CT (LDCT) lung screening scan as a green light to resume smoking, a post hoc analysis of the National Lung Screening Trial (NLST) found. For example, highly nicotine dependent...
  • Hunting Resistance Mechanisms in RET-Fusion Lung Cancer
    (MedPage Today) -- As detected by circulating tumor DNA (ctDNA), acquired resistance to pralsetinib (Gavreto) in RET fusion-positive lung cancer was relatively uncommon, findings from the ARROW study suggested. In 42 non-small cell lung cancer...
  • Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC
    (MedPage Today) -- A first-line immune checkpoint inhibitor combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival in patients with advanced non-small cell lung cancer (NSCLC) when added to a limited course of chemotherapy...
Content Protected Using Blog Protector By: PcDrome.